日本遺伝子治療市場規模、シェア、競争環境およびトレンド分析レポート：タイプ別（遺伝子増強、遺伝子サイレンシング、その他）、ベクター別（ウイルスベクター、非ウイルスベクター）、遺伝子送達方法別（生体内、生体外）、用途別（腫瘍性疾患、遺伝子疾患、心血管疾患、神経筋疾患、血液疾患、感染症、その他）、投与経路別（静脈内、その他）、エンドユーザー別（病院、がんおよび研究機関、クリニック、その他）： 2025年から2033年までの機会分析および業界予測

レポートID : ROJP1125906 | 最終更新 : 2025年11月 | フォーマット : : :

JAPAN GENE THERAPY MARKET REPORT - TABLE OF CONTENTS

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY

4. VOICE OF CUSTOMER

5. MARKET DYNAMICS

5.1. Market Overview
5.2. Demand Supply Analysis
5.3. Import and Export Analysis
5.4. Value Chain Analysis
5.5. Porter’s Five Forces Analysis
5.6. PESTLE Analysis
5.7. Pricing Analysis
5.8. Market Dynamics
5.9 MARKET DRIVERS
- 5.9.1 Increasing Investments to Support Market Expansion
5.10 MARKET RESTRAINTS
- 5.10.1 High cost of gene therapies 
5.11 MARKET OPPORTUNITY
- 5.11.1 Rising Collaborations to Bolster Market Growth
5.12 PORTER'S FIVE FORCE ANALYSIS
- 5.12.1 Bargaining Power of Buyers/Consumers
- 5.12.2 Bargaining Power of Suppliers
- 5.12.3 Threat of New Entrants
- 5.12.4 Threat of Substitute Products
- 5.12.5 Intensity of Competitive Rivalry

6. MARKET SEGMENTATION (Market Size by Value - USD 2025-2033)

6.1 By Type
- 6.1.1. Gene Augmentation
- 6.1.2. Gene Silencing
- 6.1.3. Others
6.2 By Vector
- 6.2.1. Viral Vectors
- 6.2.2. Non-Viral Vectors
6.3 By Gene Delivery Method
- 6.3.1. In vivo
- 6.3.2. Ex vivo
6.4 By Application
- 6.4.1. Oncological Diseases
- 6.4.2. Genetic Diseases
- 6.4.3. Cardiovascular Diseases
- 6.4.4. Neuromuscular Diseases
- 6.4.5. Hematological Diseases
- 6.4.6. Infectious Diseases
- 6.4.7. Others
6.5 By Route of Administration
- 6.5.1. Intravenous
- 6.5.2. Others
6.6 By End-user
- 6.6.1. Hospitals
- 6.6.2. Cancer and Research Institutes
- 6.6.3. Clinics
- 6.6.4. Others
6.7 By Region
- 6.7.1. North [Hokkaido and Tohoku]
- 6.7.2. Central [Kanto and Chubu]
- 6.7.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]